Compare Gitlab Inc (GTLB) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gitlab Inc vs Pfizer Inc — how do they compare? Gitlab Inc trades at $40.98 (market cap $6.89B), while Pfizer Inc trades at $26.48 (market cap $149.96B). The key difference: Pfizer Inc is far larger — about 21.8× Gitlab Inc's market cap, and Pfizer Inc pays a 6.54% dividend while Gitlab Inc pays none. Which is the better fit depends on your goals.
| GTLB | PFE | |
|---|---|---|
Market Cap | $6.89B | $149.96B |
Sector | Technology | Health |
52-Week High | $51.04 | $28.56 |
52-Week Low | $19.42 | $23.60 |
Enterprise Value | $5.63B | $201.45B |
Volume | — | 29,869,932 |
Dividend Yield | — | 6.54% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GitLab (GTLB) trades at $40.93, up 0.49% today, with a bullish technical signal from moving averages but overbought RSI readings above 90. The company reported strong revenue growth, reaching $759 million in 2025, and has beaten EPS estimates for three consecutive quarters. Recent news highlights its leadership in DevSecOps and AI-driven platform enhancements, including the launch of GitLab 19.2 and a collaboration with Google Cloud.
Outlook remains mixed; analyst consensus is cautious with a $32.92 price target below the current price, citing high valuation multiples like a P/E of 521.22. Risks include persistent negative cash flow and profitability challenges, though growth in AI and enterprise adoption offers long-term potential. Investors should weigh high valuation against robust revenue expansion and market position.
Pfizer (PFE) trades at $26.62, down 1.59% with a bullish technical signal. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analyst consensus is mixed with 38% buy ratings and a $27.86 price target. Recent news highlights Pfizer's pipeline developments in oncology and obesity treatments, positioning for future growth despite patent cliff concerns.
Pfizer presents a value opportunity with defensive cash flows and dividend yield, but faces patent expiration risks and competitive pressures. The stock trades below analyst targets with strong institutional support, though margin compression and pipeline execution remain key watchpoints for investors seeking pharmaceutical exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gitlab Inc
GitLab Inc operates on an all-remote model. The company is a technology company whose primary offering is GitLab, a complete DevOps platform delivered as a single application. GitLab is used by a wide range of organizations. The company also provides related training and professional services. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. The principal markets for GitLab are currently located in the United States, Europe, and Asia Pacific. The company is focused on accelerating innovation and broadening the distribution of its platform to companies across the world.
Read more on GTLB →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
